3 Overlooked Small-Caps Worth Watching in a 28-VIX Market
When the market is on fire, the best opportunities are the ones nobody is screaming about on YouTube

Ticker Ratings
The VIX just spiked 69.66% in a single session to 28.18, the S&P 500 shed 4.36% in one day, and your Twitter feed is a rotating cast of geopolitical doomers and AI permabulls shouting at each other. Classic. This is exactly the kind of noise that buries genuinely interesting small-cap stories under an avalanche of hot takes about tankers and midterm politics.
So here are three tickers worth your actual attention. None of them are household names. That's the point.
$CSWI (CSW Industrials) is the quiet industrial compounder that capital allocators dream about and retail investors have never heard of. The company makes HVAC components, plumbing products, and electrical specialty items through a disciplined acquisition strategy. Market cap sits comfortably under $5B, it has zero analyst celebrity coverage, and it generates consistent free cash flow in a sector that tends to hold up when the broader market gets shaky. The catalyst: a pending bolt-on acquisition pipeline that management has telegraphed for the back half of fiscal 2027. If they close even one deal at a reasonable multiple, this thing re-rates quietly while everyone else is watching Nvidia move in real time.
$LQDT (Liquidity Services) runs online auction marketplaces for surplus and salvage assets, including government equipment, retail returns, and commercial surplus inventory. Under $500M market cap, deeply unsexy, and completely invisible to the influencer-finance crowd. Here is the interesting part: in volatile, recessionary-leaning environments, surplus and liquidation markets historically see volume spikes. Companies cut capex and sell equipment. Retailers unload returns faster. $LQDT gets busier exactly when the economic mood gets worse. With the VIX elevated and macro jitters real, this counter-cyclical niche deserves a look. Catalyst: their government marketplace vertical is up for contract renewal with the DoD, and a confirmed renewal would be a clean near-term re-rating event.
$CTKB (Cytek Biosciences) is a life sciences instruments company making spectral flow cytometry systems, which basically means very precise cell analysis tools for research labs and biopharma. Market cap is well under $1B, it got obliterated during the 2022 biotech washout and never fully recovered, and the buy-side has largely moved on. The bull case: biopharma spending on research tools tends to lag the drug approval cycle by 12-18 months, and there is a real pipeline of approvals in immunology and oncology building. The bear case: instrument companies need their customers to have budget, and tighter grant funding is a real headwind. Worth watching the next earnings call for instrument placement numbers as the leading indicator.
None of these will save you if the S&P drops another 4% tomorrow. But in six months, when everyone is asking what they missed while they were glued to the tanker drama, these are the kind of names that quietly do the work.